Other Indications |  Print This Page  |  Resources For US Healthcare Professionals

ACR Response
ACR response to CIMZIA monotherapy was significant at Week 1 and sustained at Week 241

Significant ACR20 response
CIMZIA demonstrated a significant ACR20 response at Week 24 (the primary end point), with a 45.5% response rate versus 9.3% for placebo (P<.001). ACR20 response was notable from Week 1 (37%).1,2

Significant ACR50 and ACR70 responses
ACR50 and ACR70 responses at Week 24 (secondary end points) were also significantly better with CIMZIA (22.7% vs 3.7% and 5.5% vs 0%, respectively).

FAST4WARD: Significant ACR Response at Weeks 1 and 8, and Lasting to Week 24 (mITT pop.)1,2

Click to enlarge
Similar results were seen in Study 014.
*P<.05. Placebo values were 7% at Week 1, 0% for ACR50 at Week1, and 0% for ACR70 at Week 8.
†P<.001 for all except ACR70, P.013. Placebo values were 9% for ACR20, 4% for ACR50, and 0% for ACR70 at Week 24.

Rare reports of blood dyscrasias have been reported with CIMZIA; patients should be advised to seek medical attention if these develop.


References:
1. Fleischmann R, Vencovsky J, van Vollenhoven RF, et al. Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study. Ann Rheum Dis. 2009;68:805-811.
2. Data on file. UCB, Inc.; Smyrna, GA.
Your patients may be
eligible to save up to
$500 per pack on
CIMZIA prescriptions